CNS Pharmaceuticals Inc. (CNSP) stock face both trends on Thursday, March 18, 2021. It gained 5.65% in the normal trading session but lost 6.02% in the extended trading session. Still, there is no recent development supporting its loss and gains.
Let’s have a look at the recent news of CNSP.
Participation in Inaugural Emerging Growth Virtual Conference
CNSP participated in the Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC which took place virtually on March 17th and 18th. The company was represented by CNSP CEO John Climaco.
Participation in H.C. Wainwright Global Life Sciences Conference
The CNSPharmaceuticals also participated in H.C. Wainwright Global Life Sciences Conference which took place virtually on March 9-10, 2021.CEO John Climaco presented the company.
Commencing of Berubicin Trial
On February 25, 2021, the CNSP announced thatthe clinical program for Berubicin will start enrolling patients in March 2021.
Berubicin is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of several serious brain and CNS oncology indications.
Berubicin Supply Agreement with WPD Pharmaceuticals
On February 24, 2021, WPD Pharmaceuticals signed an agreement with CNSP to obtain an Investigational Medicinal Product for use in the planned clinical trials of Berubicin.
According to the agreement, half of the batch previously manufactured for CNS by BSP Pharmaceuticals for the WPD-201 and WPD-201P studies will be purchased by the WPD.
About the Company
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. CNS holds a worldwide exclusive license to the Berubicin chemical compound which is proposed for the treatment of glioblastoma multiforme.
John M. Climaco, Esq. is the CEO of CNS Pharmaceuticals. He has 15 years of experience in different leadership roles in different healthcare companies.